Genetically engineered immunotoxin shows early promise in patients with B-cell malignancies

(American Association for Cancer Research) DT2219, a new bispecific ligand-directed diphtheria toxin, was found to be safe and clinically effective in a small group of patients with relapsed/refractory B-cell malignancies, according to phase I clinical trial data.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news